ABSTRAm. In juvenile rheumatoid arthritis (JRA), it is likely that the release of proteolytic enzymes from activated synovial fluid neutrophils overwhelms the major protease inhibitor, a2-macroglobulin (a*-MG), and leads to cartilage destruction. Due to the unique nature of the a2-MG-protease complex, proteolytic function is maintained until the complex is cleared. In this study, we sought to determine the concentration of a2-MG-protease complexes in synovial fluid of patients with JRA, the proteolytic activity found in their synovial fluid, and whether the a2-MG complexes are associated with increased proteolytic activity. The JRA patients' synovial fluids had complex levels of 217.0 + 192.2 nmol/L-significantly elevated compared with plasma values (p < 0.001) and with control synovial fluid (p < 0.05). Elastase activity (almost entirely neutrophil elastase) was detectable in all JRA synovial fluid samples (mean 2.9 f 2.6 mg/L) and significantly correlated with a2-MG-complex values ( r = 0.67, p < 0.01). Synovial fluid tryptic activity was detectable in all JRA patients but did not significantly correlate with a 2 -MG complexes ( r = 0.53, p > 0.05). Seventy-four percent of total elastase activity and 41% of total tryptic activity were contained in the a2-MG-complex fractions. We suggest that the increased concentration of synovial fluid a 2 -MG complexes with retained elastase activity contributes to continued proteolysis and joint destruction and may affect the subsequent disease course through its role as a modulator of IL-6. The release of these proteases may overwhelm the natural protease inhibitors, leading to cartilage destruction (6) . On clinical. serologic, and immunogenetic grounds, JRA is distinct from adult rheumatoid arthritis and consists of several distinct subtypes. However, the synovial fluid and synovial lesions are indistinguishable (7).
The major protease inhibitor found in plasma is n2-MG (I). Binding of proteases to a bait region on a:-MG initiates a conformational change. during which the protease becomes trapped within the n2-MG molecule (8. 9) . This change reveals a receptor-recognition site that permits rapid and selective clearance of tr2-MG complexes from the circulation by the reticuloendothelial system. Consequently, all of the n2-MG found in the systemic circulation is believed to exist in the uncomplexed form (10, 11) . Due to the unique nature of the protease-02-MG complex. the proteolytic function is maintained until the complex is cleared ( 12) . The mechanism involved in the clearance of synovial fluid n2-MG complexes is unknown, although it probably is via macrophage uptake ( 13) .
Abbink el a/. (14) have recently shown that synovial fluid n r MG is inactivated by complex formation with neutrophil proteases and reactive oxygen species. The authors hypothesize that inactivation of a2-MG through the release of reactive oxygen species and proteases by neutrophils contributes to tissue damage by facilitating the action of uninhibited proteoglycan-degrading proteases. In this study. we sought to determine the concentration of n2-MG complexes in synovial fluid of patients with JRA, the proteolytic activity found in their synovial fluid, and whether the n2-MG complexes are associated with increased proteolytic activity.
MATERIALS AND METHODS

S1thjr
.c.t.~. Synovial fluid was obtained from 18 patients ( 1 2 females. six males; mean age 8.4 y, range 2.0 to 18.9) who satisfied diagnostic criteria for JRA and had active disease (13 Proteolytic enzymes in plasma are derived from the breakdown pauciarticular, five polyarticular-1 with associated psoriasis). of bacterial and host cells and may be generated during coagu-Control synovial fluid ( n = 4) was obtained from three adult lation, fibrinolysis, and phagocytosis (1). Large numbers of phag-patients with osteoarthritis and one child with reflex sympathetic mytic cells are present in the synovial fluid of adults with dystrophy. The synovial fluid was obtained by arthrocentesis. A competitive binding assay demonstrated that the antibody was specific for a neoantigen expressed on a2-MG when the inhibitor reacts with proteases or with methylamine (16) . In addition, we have demonstrated that the ELISA is specific for a?-MG complexes and not for native al-MG ( 17) .
An ELISA was developed by coating microtiter wells with the antibody and residual binding sites with 2% BSA. Samples were then added to the wells, incubated with rabbit IgG-anti-human a2-MG (Boehringer Mannheim, Indianapolis, IN), and detected with an IgG-anti-rabbit alkaline phosphatase conjugate (Sigma Chemical Co., St. Louis, MO). A standard curve using a2-MGcomplex standards was generated on each plate. The results did not vary by more than 20%. using two dilutions within the standard curve generated on each plate. All determinations were performed in triplicate with the resulting mean + SEM taken as the value for that patient.
Elastase activity. An assay for elastase activity was prepared by using a modification of the method of Tanaka et a/. (18) . A standard curve was prepared using porcine pancreatic elastase (Sigma) diluted I: 10 000 in Tris buffer (1 7.76 g of Tris HCI and 10.6 g of Tris base/L, pH 8.0) with 10 mL of 1 % BSA/L. A 25-nM solution of the synthetic substrates N-succinyl-(L-ala)3-pnitroanilide (pancreatic elastase, Sigma) and N-methoxysuccinyl-L-ala-L-ala-L-pro-L-val-p-nitroanilide (most sensitive to levels of neutrophil elastase, although there was a slight response to pancreatic elastase; Sigma) in DMSO (Sigma) was prepared. Ten pL of substrate were added to 180 pL of Tris solution before incubation. Elastase levels were assessed by measuring the rate of hydrolysis of the substrates over time after the addition of a 20-pL sample and expressed as ng/mL. Neutrophil elastase activity was determined by comparing results obtained from the two different substrates. Standards were assayed in duplicate and specimens in triplicate with the resulting mean + SEM taken as the value for that patient.
Tryptic activity. A modification of the method of Hummel (19) was used to determine the tryptic activity in plasma and synovial fluid. In this modification, 2.6 mL of a Tris-base solution (0.04 M, pH 8.1) containing 0.01 15 M CaC12 was used to make a solution (0.001 M) ofthe low-molecular-weight synthetic substrate p-tosyl-L-arginine methyl ester (Sigma) that is not specific but most sensitive to overall trypsin activity. To this mixture, 50 pL of plasma were added at 30'C and the solution was immediately pipetted into a 3.0-mL quartz cuvette and placed in a Perkin-Elmer UV/VIS spectrophotometer (Oak Brook Instruments, Oak Brook, IL). The rate of hydrolysis of p-tosyl-Larginine methyl ester was determined by the increase in absorbance at 247 nm: the enzyme activity was expressed as the change in OD/h/mL fluid with results given as mean + SEM.
Columnjactionation. Synovial fluid from seven patients who had elevated concentrations of a2-MG complexes was separated using a Sephacryl 300 (Pharmacia, Piscataway, NJ) gel filtration column (60 x 1.6 cm). The gel was equilibrated and elution performed with 50 mM Tris-HC1 (pH 7.6) containing 0.14 M NaCl. One-mL samples were applied to the column, and 2-mL fractions of the eluant were collected. The column was calibrated with blue dextran (2000 kD), a2-MG (720 kD), BSA (66 kD), and vitamin B12 ( 1 kD) (Sigma). Samples beginning with the void volume were pooled in groups of three (6 mL) and concentrated to 1 mL using a Minicon Macrosolute concentrator (Amicon, Danvers, MA). Fractions corresponding to a2-MG complexes and uninhibited proteases were collected separately and analyzed to determine whether increased proteolytic activity was associated with the complexes or with free proteases.
Statistics. Results from patient groups were compared by the Wilcoxon rank sum test and corrected for multiple-group comparisons, where applicable. The significance of an association between a*-MG complexes and proteolytic activity was determined by Spearman rank correlation. Table I ). There was no significant correlation between the levels obtained from the four patients who went into remission compared with the levels seen in the patients who Synovial fluid tryptic activity was detectable in all patients with JRA, corresponding to a concentration of 20 to 30 mg of trypsin/mL. The three patients with complex concentrations in the range of the control synovial fluid had detectable but de- 
Mean + SEM * Abbreviations are the same as those in Table I creased proteolytic activity compared with those patients with higher concentrations of a2-MG complexes (5.1 * 1.9 AOD/h/ mL versus 20 Proteolytic activity associated with a2-MG comple,ues. ELISA determination of all fractions after column fractionation demonstrated a recovery of 85.4% of the total a2-MG complexes. Elastase activity was determined from all fractions separately to determine the percentage of total synovial fluid activity associated with the a2-MG complex fraction. In the patients with elevated a2-MG complex levels (and increased elastase activity), 73.6% of total elastase activity was contained in the a2-MGcomplex fractions, whereas only 8.4% of elastase activity was associated with fractions that contained free proteases ( Table 2 ). The percentage of elastase that was found in the a2-MG-complex fraction was significantly correlated with the total elastase activity ( r = 0.86, p < 0.05). Tryptic activity was also analyzed from the different fractions, with 41 % of total activity associated with the a2-MG-complex fraction. However, the change in O D determined from the a2-MG complexes did not significantly correlate with total tryptic activity ( r = 0.4, p > 0. I, data not shown).
DISCUSSION
Progressive joint destruction in rheumatoid arthritis may be related to proteolytic enzyme release and damage to articular cartilage. As the major protease inhibitor. a2-MG is postulated to play a pivotal role in the balance between active protease release and clearance. The formation of a2-MG complexes leads to a conformational change in a2-MG, facilitating rapid and selective clearance by the reticuloendothelial system ( 10, 1 1 ) . Due to the unique nature of the a2-MG-protease interaction, complexes retain enzymatic activity against low-molecularweight substances (12) . Therefore, effective inhibition requires both rapid binding and rapid clearance of the protease complexes. In rheumatoid arthritis, a2-MG, as a major inhibitor of elastase and cathepsin G (20, 21) . can function in joint protection. In addition, a2-MG has been shown to function as a modulator of IL-6, which is present in high levels in synovial fluid from patients with rheumatoid arthritis (22, 23) .
We have demonstrated that synovial fluid from patients with JRA have significantly increased concentrations of a2-MG complexes. Our results are similar to the findings of Abbink et a/. ( 14) . who demonstrated increased concentrations of az-MG complexes in the synovial fluid from adult patients with rheumatoid arthritis. In addition, similar to findings in adult rheumatoid arthritis (24), we have demonstrated that synovial fluids from patients with JRA have increased proteolytic activity in large part due to neutrophil elastase. Finally, we have shown that a major part of this increased synovial fluid proteolytic activity (especially that due to neutrophil elastase) is due to the a2-MGprotease complexes rather than to free, uninhibited proteases. The increased elastase activity associated with the complexes occurred both in patients with pauciarticular as well as polyarticular disease and did not correlate with the actual a2-MG complex level or with the clinical outcome (Tables 1 and 2 ). This suggests that tissue damage in JRA may be due to the continued high synovial fluid concentrations of a2-MG complexes rather than uninhibited proteolysis after a2-MG inactivation as suggested by Abbink rt al. (14) . although other factors may be involved to explain the lack of association with disease outcome. The possible mechanisms involved in joint destruction from a2-MG complexes may be through the retained enzymatic activity of the complexes to small-molecular-weight substances ( I 2). leading to direct joint damage, or by changes in the balance between proteases and other smaller-molecular-weight antiproteases. A second possibility is that because u2-MG has been shown to function as a modulator of IL-6 (22) . increased a2-MG bound to proteases may affect that role, leading to changes in activity of IL-6 and thereby affecting joint inflammation.
Clotting of samples leads to the activation of several proteolytic enzymes that might serve as a source of a2-MG complexes (25) . To prevent in vitro protease generation and complex formation. we collected our samples with a method previously tested and found capable of preventing clot formation (1 5). Blood collected by this method did not contain detectable levels of fibrinopeptide A, suggesting that proteolytic cleavage does not occur. In addition, we have used this method previously (26) and demonstrated that this method of collection did not lead to the generation of proteases that stabilize a2-MG. We have also previously demonstrated (17) that the method used. including sodium citrate, prevented the development of complexes from blood coagulation. Finally, the same method of blood sampling was used in all groups. Based on these considerations, we believe that the method of sample collection could not explain the results and the differences noted in this study.
It is interesting to note that two of three JRA synovial fluids with low concentrations of a2-MG complexes and low proteolytic enzyme activity were from patients with pauciarticular disease. Neutrophil and 82-microglobulin levels have been found to be lower in pauciarticular patients compared with those with polyarticular disease and has been postulated to identify patients with decreased risk of severe erosive joint destruction (27) . It should also be noted that all three patients with synovial fluid a2-MG complex values in the control range achieved remission over the follow-up period. The concentration of a2-MG complexes may similarly be useful in prognostication regarding the risk of erosive disease. Long-term follow-up of our patients and further study is necessary to determine if this is the case.
In this study, we have also demonstrated that normal control children have significantly increased plasma concentrations of a?-MG complexes compared with adults. Plasma levels of a 2 -MG complexes reflect a balance between complex formation and the rapid reticuloendothelial clearance of these complexes (10, 11) . These results confirm our previous findings (using an indirect method to assess plasma levels of a2-MG complexes) that healthy 3-d-old infants have elevated levels of complexes compared with adults (26) . We suggest that increased plasma concentration in newborns may be a response to excessive protease uptake across an immature intestinal bamer (28) or may reflect delayed clearance of these complexes by the reticuloendothelial system. Future studies will be needed to assess a2-MGcomplex clearance in children and to determine whether the increased plasma levels of complexes lead to increased plasma proteolytic activity.
These data suggest that neutrophil activation in JRA leads to release of proteolytic enzymes including elastase into the synovial fluid. Proteases are rapidly bound to a2-MG, but a2-MG complexes accumulate due to poor clearance from the joint. The increased concentration of synovial fluid a2-MG complexes with retained proteolytic activity contributes to continued proteolysis and joint destruction and may affect the subsequent disease course through its role as a modulator of IL-6 (22) . Future studies, including serial measurements of synovial fluid a2-MG complexes and proteolytic activity and the correlation between those results and disease activity, will be important in determining the value of an individual determination in a child with JRA. Therapeutic interventions that increase clearance of a2-MG complexes or provide other intraarticular protease inhibitors that function without retaining proteolytic activity (a,-protease inhibitor) may prove useful in JRA.
